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Dose responseHexavalent chromium (Cr6) is a drinkingwater contaminant that has beendetected inmost of thewater systems
throughout the United States. In 2-year drinking water bioassays, the National Toxicology Program (NTP) found
clear evidence of carcinogenic activity in male and female rats and mice. Because reduction of Cr6 to trivalent
chromium (Cr3) is an important detoxifying step in the gastrointestinal (GI) tract prior to systemic absorption,
models have been developed to estimate the extent of reduction in humans and animals. The objective of this
work was to use a revised model of ex vivo Cr6 reduction kinetics in gastric juice to analyze the potential reduc-
tion kinetics under in vivo conditions for mice, rats and humans. A published physiologically-based pharmacoki-
netic (PBPK) model was adapted to incorporate the new reduction model. This paper focuses on the
toxicokinetics of Cr6 in the stomach compartment, where most of the extracellular Cr6 reduction is believed to
occur in humans. Within the range of doses administered by the NTP bioassays, neither the original nor revised
models predict saturation of stomach reducing capacity to occur in vivo if applying default parameters. However,
bothmodels still indicate that mice exhibit the lowest extent of reduction in the stomach, meaning that a higher
percentage of the Cr6 dose may escape stomach reduction in that species. Similarly, both models predict that
humans exhibit the highest extent of reduction at low doses.
Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).IntroductionHexavalent chromium (Cr6) is recognized as toxic and carcinogenic
to humans via the inhalation route, while chronic low-dose effects via
the oral route are not as well characterized (ATSDR, 2012; IARC, 2012;
OSHA, 2006). Determining potential health effects in humans exposed
orally is of interest since Cr6 has been detected in public water systems
throughout the United States (USEPA, 2015). In 2008, the National
Toxicology Program (NTP) concluded that there was clear evidence of
carcinogenic activity of Cr6 (administered as sodium dichromate
dihydrate [SDD] in drinking water) in male and female F344/N rats
and male and female B6C3F1 mice. The NTP study observed increased
incidences of squamous cell neoplasms of the oral cavity of rats, and
increased incidences of neoplasms of the small intestine of mice (NTP,
2008; Stout et al., 2009). The mode of action (MOA) for Cr6-induced
tumors at the cellular or subcellular level (Thompson et al., 2013; Witt
et al., 2013) is a topic outside the scope of this paper. This work will
focus on an important extracellular toxicokinetic step that may inﬂu-
ence interpretation of interspecies differences in toxicity.losser.paul@epa.gov
ss article under the CC BY license (htIt is generally understood that the reduction of Cr6 to Cr3 in the
gastrointestinal tract is a detoxiﬁcation pathway, and that this process
competes with the rapid uptake of Cr6 into epithelial cells (Costa,
1997; Stern, 2010; Zhitkovich, 2011). Following in vivo studies in
rodents, mice were found to have accumulated more chromium than
rats (Kirman et al., 2012; Collins et al., 2010). This may indicate more
effective absorption and/or less effective Cr6 reduction in the mouse.
A variety of ex vivo studies have been performed in the gastric juices
of humans and rodents to estimate the rate of Cr6 reduction in the stom-
ach (De Flora et al., 1987, 1997, 2008; Proctor et al., 2012). Kinetic
models derived from ex vivo reduction data have been incorporated
into whole-body physiologically-based pharmacokinetic (PBPK)
models to estimate in vivo absorption of Cr6 (Kirman et al., 2012,
2013). They have also been applied to estimate the ﬂux of unreduced
chromium from the stomach to the duodenum, which does not neces-
sarily require the whole-body PBPK model (Thompson et al., 2014,
2015).
The reduction model presented by Proctor et al. (2012), which
serves as the basis for those analyses, considers only a single pool of
reducing agent. Upon examination of the raw data, it was determined
that a single pathway assumption does not adequately ﬁt the data at
high doses, and that 100% depletion of reducing agent at the high
doses cannot be inferred from these data. Therefore, an alternativetp://creativecommons.org/licenses/by/4.0/).
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duction and mechanistic information regarding the speciation of Cr6 as
a function of concentration and pH (Schlosser and Sasso, 2014).
Conceptually, this model is similar to that of Proctor et al. (2012),
since it also assumes 2nd order reactions with depleting amounts of
reducing agents. Kinetic models, assuming multiple reduction path-
ways, were shown to ﬁt the published ex vivo data signiﬁcantly better
than alternative models that assumed a single pathway for reduction
(Schlosser and Sasso, 2014). Furthermore, the revised model better
captures the observed dependence of reduction rate on pH and the
dilution or amount of reducing agent, factors that are expected to vary
in vivo. The current work incorporates the improved kinetic models
into the gastric transit portion of the PBPK model by Kirman et al.
(2012, 2013). The impact of the revised kinetics on model outputs is
assessed, and the applicability of some internal dose metrics for species
extrapolation is evaluated.
Materials and methods
The primary GI model structure for transit is unchanged from
Kirman et al. (2012), and is illustrated by Fig. 1. The model was
developed in the Advanced Continuous Simulation Language (ACSL)
using acslXtreme software (Aegis Technologies, Huntsville, AL), and
modiﬁed from the code published by Kirman et al. (2012). The order
of GI transport is stomach→ duodenum→ jejunum→ ileum, and each
lumen compartment has a different length, volume, andpH. For thepur-
poses of this work, loss of chromium to systemic circulation is neglected
in order to focus solely on gastric transit and reduction kinetics, and to
assess inter-species differences that are not sensitive to the systemic
PBPK model. Furthermore, the gastric physiology of both the revised
model and the Kirman et al. (2012)model is held constant. Thus, “stom-
ach-only”model simulations provide a uniform comparison of the im-
pact of the revised ex vivo reduction model on potential downstream
in vivo kinetics.
The original, relatively simple GI reduction kinetic model, which
assumed only a single pool of reducing agent, was replaced with the
revised GI reductionmodel (Schlosser and Sasso, 2014), which assumes
multiple pools of reducing agents for mice and rats and amore complex
dependence on pH in all species. Reducing agents are generated from
constituents in the gastric juices in the stomach (the volume of which
is a function of dietary/water intake and body weight) and travel
through the GI tract, leading to a steady-state baseline level of these
agents in each GI compartment. Upon ingestion, Cr6 is converted to
Cr3 by the reducing agents from binary reactions, and the rates of loss
of both reactants (Cr6 and reducing agent) are equivalent (i.e., a
one-to-one stoichiometry is assumed). Reduction in each GI lumen
compartment occurs as a function of compartment- and species-
dependent GI characteristics (i.e., pH, lumen volumes, and transit
rates). The revised kinetic model tracks multiple chemical species into
which Cr6 is incorporated and assumes that these have distinct levels
of reactivity with reducing agents. The chemical speciation is pH-Fig. 1. Schematic diagram of the gastrointestinal sub-model of the chromium PBPK model. Tdependent, which in turn leads to the pH-dependence in reduction
rates (Brito et al., 1997). The model also assumes that in rodents three
reducing agents exist in gastric juices (instead of a single reducing
agent and one reduction pathway). For humans, the Proctor et al.
(2012) data were insufﬁcient to identify distinct pools of reducing
agents, so only one pool is simulated. Additional details are provided
in the Supplementary materials.
While Cr6 transport via absorption or sloughing likely occurs in the
stomach, the rates of these processes are expected to be much slower
than ingestion, reduction, and transport to the duodenum. So for
simplicity, absorption and sloughing are neglected, hence the stomach
lumen mass balance for Cr6 is:
dASL6
dt
¼ Cr6oral intakeratef g−KLSD
 ASL6− totalCr6reductionratef g
where ASL6 is amount of Cr6 in the stomach lumen (mg), and KLSD is
the lumen transit rate from the stomach to duodenum (h−1). The oral
intake rate of Cr6 is a function of user-deﬁned exposure proﬁles, and
total Cr6 reduction rate is the sumof the reduction rates of three distinct
reduction pathways.
The rate of Cr6 reduction due to pathway 1 (i.e., reaction with the
ﬁrst reducing agent pool) is deﬁned as:
R1 ¼ k1  CSL6effð Þ  ARESL1
where the parameter k1 (deﬁned as kf in Schlosser and Sasso (2014);
redeﬁned here with numeric subscript for simplicity) is the binary
rate constant for reduction pathway 1 (L/mg-h), and ARESL1 is the
amount of reducing agent for pathway 1 in the stomach lumen (mg).
The effective concentration of Cr6 in the stomach lumen (CSL6eff) is
deﬁned as the sum of three speciated forms of Cr6, corrected for the
fractional contribution of each form to the total reduction rate. The
proportion of Cr6 in each form (and hence the ratio of CSL6eff to total
Cr6 concentration) is pH-dependent, which accounts for the roughly
inverse relationship between pH and total reduction rate. This is
described in further detail by Schlosser and Sasso (2014), and the
calculation of CSL6eff can be found in the Supplementary materials.
A mass balance is performed on the reducing agent, with the




¼ CRE01  gastric juiceformationratef g−KLSD  ARESL1−R1
where CRE01 is the reducing capacity of reducing agent 1 (in mg/L
gastric juice), and the gastric juice formation rate is deﬁned as L gastric
juice/h (see Kirman et al., 2012). The reducing agent (as a component of
gastric juice) is formed in the stomach as a function of dietary intake and
physiological processes, and eliminated to the small intestine at the
stomach transit rate. This formation rate is assumed to be constant forhe jejunum and ileum (not shown) each follow an identical scheme as the duodenum.
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plicitly describes two additional reduction pathways, simply referred
to as reduction pathways 2 and 3 here. The mass balance equations
for reduction pathway 2 are identical in form to pathway 1. Equations
for pathway 3 are outlined in the Supplementary materials.
Results
Analysis of stomach reduction
As an extension of the analysis performed in Schlosser and Sasso
(2014) and Proctor et al. (2012), which calculated Cr6 intake as a
percentage of reducing capacity, we looked at reduction that may
occur following ingestion events in vivo. Similar to the prior analysis,
this analysis was performed on the basis of water Cr6 concentration
(mg/L) and different water intake volumes for each species (0.2 mL
per bout for mice, 0.7 mL for rats). Intake events were repeated to
examine potential cumulative effects of multiple exposures over a
short time period. For illustration purposes, exposure for rodents was
repeated 23 times over the course of a 12-hour period, with some
drinking water events occurring within the same 1-hour period.
Humans were simulated as drinking 3 glasses of water (300 mL each)
within a span of approximately 20 min. The time proﬁles for the
mouse under these repeated exposure conditions at 30 ppm Cr6 are il-
lustrated in Fig. 2, and simulations for the human are provided in the
Supplementary materials.
These assumptions were then repeated for all species from 0 to
60 ppm drinking water concentrations of Cr6 (Fig. 3). Mice wereFig. 2. Simulation of hypothetical drinking water events for a 0.045 kg mouse at 30 ppm
Cr6, assuming 0.2mL drinkingwater volume per event. Total cumulative dose (23 events)
is approximately 3 mg/kg. RA (fast) indicates reducing agent for the fast reduction path-
way, while RA (slow) indicates reducing agent for the slower reduction pathway.
(A) Cr6 concentration in stomach lumen. (B) Stomach reducing agent amounts.generally found to exhibit the highest percentage of Cr6 escaping stom-
ach reduction. As a result, the mouse would have a higher downstream
internal dose in the small intestine than rats. This is consistentwith data
by Kirman et al. (2012), which found concentrations of total chromium
in the small intestine to be higher in mice than in rats when adminis-
tered equivalent concentrations of Cr6 in drinking water for 90 days.
The NTP studies found that stomach and liver tissue concentrations
(when normalized by average dose) were higher in mice than in rats
(Collins et al., 2010), which is also consistent with reduction in the
mouse stomach being less efﬁcient.
For long-term simulations performed on the basis of repeated
average daily dose in mg/kg-day, the interspecies patterns are similar
to the short-term analysis (Fig. 4(A)). Simulations for rodents assumed
that the drinking water dose was distributed throughout the day by a
circadian pattern (Spiteri, 1982; Yuan, 1993). Simulations of humans
assumed that the drinking water dose occurred as six exposure events
per day. Humans were further examined in the range of doses below
1.5mg/kg-day at varying levels of pH (Fig. 4(B)). For humans, the reduc-
tion reaction is more efﬁcient than mice or rats at low doses. The low
stomach pH and long residence time increase the rate and extent of
reaction. While the more efﬁcient reduction in humans causes less Cr6
to escape the stomach at low doses, it also leads to a sharper loss of
reducing agent with increasing dose. For rats and mice, there remains
sufﬁcient capacity for reduction of Cr6 to Cr3 in the stomach, although
the reaction is predicted to occur at a decreased rate at higher doses.
The precise relationships are uncertain, however, since rodent stomach
pH is known to vary with fed status (McConnell et al., 2008), and the
default pH applied in Fig. 3 was held constant at 4.5. Stomach pH values
measured by McConnell et al. (2008) ranged from 3 to 4. At a mouseFig. 3. Simulations of reducing agent loss (left) and Cr6 stomach reduction (right) as a
function of drinking water concentration. Reducing agent loss is presented as the mini-
mum value of reducing agent in the stomach over the exposure time period, (relative to
steady-state non-exposure conditions). Stomach reduction is presented as the percent of
the total Cr6 dose that escapes the reduction process and empties into the small intestine.
(A) Stomach reducing agent loss. (B) Stomach reduction.
Fig. 4. Simulations of Cr6 reduction in three species across a wide dose range (left), and
humans for doses below 1.5 mg/kg-day under varying pH (right). Setting model values
of pH in the range of 1–3 produces results that are indistinguishable. (A) High-dose region
(humans, mice, rats). (B) Low-dose region (humans).
Table 1
Dose–response modeling for diffuse epithelial hyperplasia in mice based on the pyloric













Mouse simulations Human simulations
Male mouseb
BMDL5 1.3 3 0.43 0.12 0.014
BMDL10 2.6 3 0.88 0.14 0.028
Female mousec
LOAEL 4.0 30 0.13 0.089 4.5e−3
10 0.40 0.12 0.013
3 1.3 0.15 0.042
a Uncertainty factors.
b Male mouse internal dose BMDLs were adjusted by a UF of 3 for the purpose of com-
parisonwith Thompson et al. (2014, 2015),who applied a UF of 3 to the internal dose (citing
interspecies variation).
c Data for the female mouse were not amenable to BMDmodeling. The LOAEL was ad-
justed by UF values of 3, 10, and 30 to account for extrapolation of a LOAEL to NOAEL and
interspecies variation. These UF values were applied for model evaluation purposes only
and do not reﬂect an evaluation of the toxicology data for the mouse.
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and high doses would be greater.
Inter- and intra-individual differences in pH, baseline stomach acid
secretion, or stomach size and emptying rate may have a signiﬁcant
impact on model results. Some humans in the population exhibit
consistent extremely high stomach pH due to a condition called
hypochlorhydria (Kalantzi et al., 2006; Feldman and Barnett, 1991;
Christiansen, 1968). The fraction of the human population exhibiting
this condition is unknown, but a large percentage of a Cr6 dose may
escape the stomachs of these individuals (Fig. 4(B)). Among healthy
adults without hypochlorhydria, 5% of men may still exhibit basal pH
exceeding 5, and 5% of women may exhibit basal pH exceeding 6.8
(Feldman and Barnett, 1991). For the average human adult, stomach
pH will increase temporarily to 6 during meals (Parrott et al., 2009).
Daily variation in gastric emptying is also expected to occur. Gastric
emptying half time of liquids in non-fasted individuals is typically
higher than 35 min, while in fasted individuals it may be as low as
4–12 min (DeSesso and Jacobson, 2001; Mudie et al., 2010, 2014). The
default value used for the gastric emptying rate in this model
corresponds to an emptying half-time in the stomach of 35 min.
Comparison of human equivalent dose (HED) estimates with previous
published analysis
The study by Thompson et al. (2014, 2015) derived an HED of
0.06 mg/kg-day for the small intestine hyperplasia endpoint observed
in mice in the 2-year NTP drinking water bioassay (NTP, 2008). In that
analysis, dose–response modeling was performed on hyperplasia
incidences of individual segments of the male and female mouse small
intestine simultaneously, using the whole-body PBPK model. The
analysis was based on a 5% response rate, with an uncertainty factor of3 applied prior to human extrapolation to represent interspecies
variation. High doses were dropped and incidences in the jejunum
were neglected. Human simulations were then performed for multiple
lifestages, which accounted for circadian changes in stomach parame-
ters such as emptying rate and pH. The human extrapolation using the
kinetics presented in this paper (Table 1) did not combine data for
both sexes andmultiple individual small intestine segments, did not uti-
lize a whole-body PBPKmodel, and did not perform simulations for dif-
ferent human lifestages or circadian variation. Despite these
simpliﬁcations, the average of the HEDs of low and high stomach pH
simulations in Table 1 ranges from 0.05 to 0.1 mg/kg-day, depending
on choices for response rate and uncertainty factor, bracketing the
value of Thompson et al. (2014, 2015).
Animal-to-human extrapolation in Table 1 was performed using the
pyloric ﬂux internal dose metric, which is deﬁned by Thompson et al.
(2014, 2015) as the mass of unreduced Cr6 transferred from the stom-
ach to the small intestine normalized to small intestinal tissue volume.
While it does not require a whole-body PBPK model, the metric is
strongly informed by gastric physiology and toxicokinetics. The choice
of uncertainty factors is outside the scope of this paper; uncertainty
factors were applied in Table 1 only for the purposes of maintaining a
consistent comparison with the previously published dose–response
analysis. Animal and human variation in stomach pH and emptying
rate may have a signiﬁcant impact on the estimated HED. Additional
factors involving gastrophysiology and toxicodynamics, which are not
incorporated in the models, may also contribute to differences in
response between species. Detailed analyses incorporating population
variability and uncertainty of human and mouse gastric parameters
are the subject of ongoing work.
Discussion
Themodel for reduction kinetics used in this paper to simulate in vivo
gastrointestinal kinetics of Cr6 contained signiﬁcantly different assump-
tions for reducing capacities and pH-dependency than the kinetic model
used by Kirman et al. (2012). Despite these differences, both models are
in agreementwith respect to the overall interspecies trends: 1) mice are
estimated to exhibit less efﬁcient reduction of Cr6 in the stomach when
compared to rats; and 2) the standard reference human with a stomach
pH of 2.5 is predicted to reduce Cr6 more effectively than rodents at low
doses. Interspecies differences in stomach reduction are predicted to be a
strong function of pH and transit time. High variability in these sensitive
gastric parameters exists in the adult human population (Mudie et al.,
2010). Furthermore, neonates exhibit higher stomach pH and longer
297A.F. Sasso, P.M. Schlosser / Toxicology and Applied Pharmacology 287 (2015) 293–298emptying time, possibly due to frequent feeding (Yu et al., 2014). The net
result of high stomach pH and long stomach residence time is unknown.
Lower pH is predicted to result in faster reduction at short times and low
exposures, but may also result in faster depletion of reducing agents. A
fed stomach may have higher reducing capacity, and a longer residence
timemay allow for the reduction of Cr6 to occur to a greater extent prior
to stomach emptying, but has a higher pH in humans. Similarly, proton
pump inhibitors (PPI) decrease gastric acid production,while potentially
decreasing gastric emptying rate (Sanaka et al., 2010). For these cases,
Cr6 exposure to the small intestine may decrease, but there may be
added Cr6 exposure to the stomach epithelium (since both the stomach
emptying and detoxiﬁcationwould be occurringmore slowly). Effects in
the stomach are not directly addressed by the internal dose metrics ex-
plored in the current work since it is not a target tissue in rats or mice,
although stomach tissue absorption is expected to be dependent on
many of the same variables.
Preliminary analysis outlined in this paper also illustrates that
mouse-to-human extrapolationmay be accomplished by using a simple
gastric reduction model. The Cr6 dose to the small intestine is primarily
a function of how effectively the stomach will reduce Cr6 to Cr3. When
the simple gastric model was exercised using similar parameters and
assumptions as Thompson et al. (2014, 2015), results were comparable
despite having neglected kinetics in the small intestine and rest of the
body. An advantage of the more focused approach is that the stomach
can be deﬁned by a fewer number of parameters than a whole-body
model. Some of these parameters have been accurately determined in
humans, allowing for more targeted analysis of potentially susceptible
subpopulations. With fewer parameters and no systemic assumptions,
gastric models may be easily revised when new data become available.
Furthermore, the stomach may best mimic the batch reaction condi-
tions of the ex vivo Cr6 reduction kinetic experiments, which are the
basis of the in vivo reduction models. The stomach is believed to hold
a single continuous pocket of ﬂuid following ingestion of drinking
water (Mudie et al., 2014). In contrast, ingested ﬂuids form multiple
discrete pockets in the small intestine after stomach emptying, and
these pockets are highly variable and not uniformly distributed
throughout the lumen (Mudie et al., 2014; Takashima et al., 2013).
The well-mixed PBPK compartment assumption is likely an inaccurate
description for the small intestine. Therefore, toxicokinetic model
predictions of Cr6 in the stomach may be more robust.
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